GMDA

Gamida: Catalysts Ahead, Looks Interesting

Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast

Why Gamida Cell Stock Is Soaring Today

GMDA Stock Price Increases Over 40% Pre-Market: Why It Happened

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR

Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares